Shares of GSK (GSK.L) surged by as much as 6.5 per cent on Thursday following the announcement of a $2.2bn settlement related to U.S. lawsuits alleging that its discontinued heartburn medication, Zantac, caused cancer. The settlement, disclosed on Wednesday, was significantly lower than anticipated, with JP Morgan previously estimating a potential cost of $3.5bn. Analysts …
